Designed for fast and efficient administration1

In the treatment of malignant hyperthermia (MH), only the RYANODEX® formulation of dantrolene sodium allows for rapid response with 1 vial, by 1 provider, in less than 1 minute.1

  • 1 life

    at risk
  • 1 vial

    for most patients
  • 1 provider

    to reconstitute
  • 1 minute

    to administer
  • 1 name

    to remember

When an MH event occurs, every minute counts.2,3 RYANODEX® (dantrolene sodium) for injectable suspension was developed to help emergency staff respond as rapidly and efficiently as possible.1

Consider the RYANODEX® difference:

Nanosuspension technology

Nanosuspension technology for rapid reconstitution and administration1,4

  • Advanced nanosuspension technology is combined with a lyophilized formulation that allows RYANODEX® to be reconstituted with sterile water for injection and administered in significantly less time compared with other formulations of dantrolene sodium1,4
    • Simplified and rapid reconstitution to prepare a single vial within 10 seconds1,4
    • Time to administer 2.5 mg/kg loading dose of RYANODEX® for a 100 kg patient is 1 minute compared to >22 minutes for other approved formulations1,4*

*Based on administration speed of 50 mL/min (16.5 mg/min).1

Fewer vials and less IV fluid

Fewer vials and less sterile water for injection

  • RYANODEX® requires fewer vials (depending on the patient) and less sterile water for injection volume compared to other dantrolene formulations5-7
    • One vial of RYANODEX® contains the same amount of dantrolene sodium as 12.5 vials of other approved formulations5-7
    • Each vial of RYANODEX® contains 250 mg of dantrolene sodium and requires reconstitution with only 5 mL of sterile water for injection vs 60 mL per vial with other formulations1,5-7
Rapid response that can help mitigate risk

Rapid response that can help mitigate risk of complications1

  • Treating patients with dantrolene sodium quickly is essential to help minimize or avoid serious complications including coma, cardiac arrest, and disseminated intravascular coagulation2,4

An initial 20-minute delay in administration of dantrolene sodium raises the risk of complications to 30%.2 With ryanodex®, dantrolene sodium can be reconstituted and administered in less than 1 minute1

Ryanodex® For
Malignant Hyperthermia

RYANODEX® is indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.7


RYANODEX® is a ryanodine receptor 1 antagonist—the only drug approved to specifically target MH. RYANODEX® is believed to inhibit abnormal calcium release from sarcoplasmic reticulum, leading to muscle relaxation.4,7

Indication and Important Safety Information